Hughes J A, Conry B G, Male S M, Eastell R
Kent & Sussex Hospital, UK.
Thorax. 1999 Mar;54(3):223-9. doi: 10.1136/thx.54.3.223.
Inhaled corticosteroids are recognised as the most effective agents in the treatment of asthma. However, concerns have been expressed about the effects of high doses of inhaled corticosteroids on safety in relation to bone resorption and formation. This study measures the effects of two inhaled corticosteroids on bone markers and bone mineral density (BMD) over one year.
A one year randomised, prospective, open parallel study comparing inhaled fluticasone propionate (FP), 500 micrograms twice daily in 30 patients, and budesonide (BUD), 800 micrograms twice daily in 29 patients, delivered by metered dose inhaler and large volume spacers was performed in adults with moderate to severe asthma. Biochemical markers of bone turnover (osteocalcin, procollagen type 1 C-terminal propeptide (PICP), immunoreactive free deoxypyridinoline (iFDpd), N-terminal crosslinked telopeptides of type I collagen (NTx)), BMD at the spine and femoral neck, and serum cortisol concentrations were measured at baseline and 12 months later.
There were no significant differences between the inhaled steroids on bone markers of bone resorption and formation or bone mineral density. Bone mineral density of the spine increased slightly in both groups over the 12 month period. Serum osteocalcin levels increased from baseline in both treatment groups (FP 16.9%, p = 0.02; BUD 14.3%, p = 0.04). PICP did not differ significantly from baseline. Both markers of bone resorption (iFDpd, NTx) varied considerably with no significant changes after one year. There was a significant correlation in percentage change from baseline between BMD of the spine and osteocalcin at 12 months (r = 0.4, p = 0.017). Mean serum cortisol levels remained within the normal range in both groups following treatment.
There was no evidence of a decrease in BMD during 12 months of treatment with high doses of either FP or BUD. The change in spine BMD correlated with the increase in osteocalcin. Studies extending over several years are needed to establish whether these findings persist.
吸入性糖皮质激素被认为是治疗哮喘最有效的药物。然而,人们对高剂量吸入性糖皮质激素在骨吸收和形成方面的安全性影响表示担忧。本研究测量了两种吸入性糖皮质激素在一年时间内对骨标志物和骨密度(BMD)的影响。
对30例中度至重度哮喘成人患者进行了一项为期一年的随机、前瞻性、开放平行研究,比较每日两次吸入500微克丙酸氟替卡松(FP)和29例每日两次吸入800微克布地奈德(BUD),通过定量吸入器和大容量储雾罐给药。在基线和12个月后测量骨转换的生化标志物(骨钙素、I型前胶原C端前肽(PICP)、免疫反应性游离脱氧吡啶啉(iFDpd)、I型胶原N端交联端肽(NTx))、脊柱和股骨颈的骨密度以及血清皮质醇浓度。
两种吸入性类固醇在骨吸收和形成的骨标志物或骨密度方面没有显著差异。在12个月期间,两组脊柱的骨密度均略有增加。两个治疗组的血清骨钙素水平均较基线升高(FP升高16.9%,p = 0.02;BUD升高14.3%,p = 0.04)。PICP与基线相比无显著差异。两种骨吸收标志物(iFDpd、NTx)变化较大,一年后无显著变化。12个月时脊柱骨密度与骨钙素相对于基线的百分比变化之间存在显著相关性(r = 0.4,p = 0.017)。治疗后两组的平均血清皮质醇水平均保持在正常范围内。
没有证据表明高剂量的FP或BUD治疗一年期间骨密度会降低。脊柱骨密度的变化与骨钙素的增加相关。需要进行数年的研究以确定这些发现是否持续存在。